How to eliminate MYCN-positive hepatic cancer stem cells to prevent the recurrence?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.Molecules (Basel, Switzerland) · 2020
   Review
2. Beyond the Warburg Effect: N-Myc Contributes to Metabolic Reprogramming in Cancer Cells.Frontiers in oncology · 2020
   Review
3. Emerging roles of Myc in stem cell biology and novel tumor therapies.Journal of experimental & clinical cancer research : CR · 2018
   Review
4. Reply to Yoshida: Liver cancer stem cells: Identification and lipid metabolic reprogramming.Proceedings of the National Academy of Sciences of the United States of America · 2018
   Article

Corrections and comments

• Commented on by
  Reply to Yoshida: Liver cancer stem cells: Identification and lipid metabolic reprogramming.2018
• Comment on
  Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as